Select publications

Baum M, Ravdin PM. Decision-making in early breast cancer: guidelines and decision tools. Eur J Cancer 2002;38(6):745-9. Abstract

Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer Abstract 2003;98(9):1802-10. Abstract

Berg WA, Gilbreath PL. Multicentric and multifocal cancer: whole-breast US in preoperative evaluation. Radiology Abstract 2000;214(1):59-66. Abstract

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003. Abstract 3

Boccardo F et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 2001;19(22):4209-15. Abstract

Chao C et al. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol 2003;21(23):4299-305. Abstract

Cobleigh MA et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughput RT-PCR assay of paraffin-embedded tumor tissues. Proc ASCO 2003; . Abstract 3415

Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Dowsett M et al. Analysis of time to recurrence in the ATAC (Arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003; Abstract 4 .

Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352(9132):930-42. Abstract

Esteban J et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue. Proc ASCO 2003;  Abstract 3416.

Fortin JM et al. Identifying patient preferences for communicating risk estimates: a descriptive pilot study. BMC Med InformDecisMak 2001;1(1):2. Abstract

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl JMed 2003;349(19):1793-802. Abstract

Henderson IC et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract

Jin Kim H et al. Sentinel lymph node drainage in multicentric breast cancers. Breast J 2002;8(6):356-61. Abstract

Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003;9(1 Pt 2):511S-5S. Abstract

Lipton A et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003;21(10):1967-72. Abstract

Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19(4):972-9. Abstract

Love N et al. Influence of prior therapy on breast cancer survivors' preferences for adjuvant systemic therapy in hypothetical scenarios. Proc ASCO 2004; Abstract 591

Moon WK et al. Multifocal, multicentric, and contralateral breast cancers: bilateral whole-breast US in the preoperative evaluation of patients. Radiology 2002 ;224(2):569 Abstract

Osborne CK et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95(5):353-61. Abstract

Paik S et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients NSABP studies B-20 and B-14. Breast Cancer ResTreat 2003;82(Suppl1):10; Abstract 16 .

Ravdin PM et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-91. Abstract

Ring A, Dowsett M. Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. Clin Breast Cancer 2003;4 Suppl 1:S34-41. Abstract

Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy for early breast cancer: how much benefitisneeded? J Natl Cancer Inst Monogr 2001;30:146-52. Abstract

Tousimis E et al. The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers. J Am Coll Surg 2003 Oct;197(4):529-35. Abstract